LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | LDN-193189 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4142 | 3970 | 1.0431 | 1.0649 |
BT-20 | Nilotinib | 3.33 | uM | LJP5 | 72 | hr | 1334 | 4174 | 3970 | 1.0511 | 1.0770 |
BT-20 | Dactolisib | 3.33 | uM | LJP5 | 72 | hr | 1334 | 1375 | 3970 | 0.3464 | 0.0154 |
BT-20 | WH-4-025 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 2805 | 3970 | 0.7065 | 0.5579 |
BT-20 | SB590885 | 0.04 | uM | LJP5 | 72 | hr | 1334 | 4237 | 3970 | 1.0671 | 1.1011 |
BT-20 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 1362 | 3970 | 0.3431 | 0.0105 |
BT-20 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3929 | 3970 | 0.9895 | 0.9842 |
BT-20 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 2698 | 3970 | 0.6795 | 0.5173 |
BT-20 | BX-912 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3753 | 3970 | 0.9451 | 0.9173 |
BT-20 | NVP-AEW541 | 0.12 | uM | LJP5 | 72 | hr | 1334 | 4059 | 3970 | 1.0222 | 1.0334 |
BT-20 | SB590885 | 0.12 | uM | LJP5 | 72 | hr | 1334 | 4065 | 3970 | 1.0239 | 1.0359 |
BT-20 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 410 | 3970 | 0.1033 | -0.3508 |
BT-20 | PIK-93 | 0.12 | uM | LJP5 | 72 | hr | 1334 | 4135 | 3970 | 1.0414 | 1.0624 |
BT-20 | LDN-193189 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3952 | 3970 | 0.9953 | 0.9930 |
BT-20 | CP724714 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3663 | 3970 | 0.9225 | 0.8832 |
BT-20 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1334 | 4028 | 3970 | 1.0145 | 1.0219 |
BT-20 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3429 | 3970 | 0.8636 | 0.7946 |
BT-20 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3659 | 3970 | 0.9215 | 0.8817 |
BT-20 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 1596 | 3970 | 0.4021 | 0.0994 |
BT-20 | Luminespib | 0.12 | uM | LJP5 | 72 | hr | 1334 | 945 | 3970 | 0.2380 | -0.1478 |
BT-20 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 2549 | 3970 | 0.6421 | 0.4609 |
BT-20 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1334 | 4117 | 3970 | 1.0370 | 1.0557 |
BT-20 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 3961 | 3970 | 0.9976 | 0.9964 |
BT-20 | Foretinib | 0.37 | uM | LJP5 | 72 | hr | 1334 | 1368 | 3970 | 0.3446 | 0.0128 |
BT-20 | PLX-4720 | 3.33 | uM | LJP5 | 72 | hr | 1334 | 3389 | 3970 | 0.8536 | 0.7795 |